Sidra Medicine, affiliated with Qatar Foundation, is proud to be among a select group of hospitals globally to provide Casgevy, an innovative one-time gene therapy utilizing CRISPR/Cas9 technology.
This therapy is now accessible in Qatar for individuals aged 12 and older suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).
According to Chief Medical Officer Prof. Ibrahim Janahi, this launch represents a significant leap forward, establishing Sidra Medicine as the first hospital in Qatar to offer such a promising gene-editing treatment, potentially leading to a functional cure. He noted that this initiative bolsters Qatar’s stature as a pioneer in advanced and precision medicine in the region.
Casgevy has garnered approvals from major international health regulatory bodies, including the Ministry of Public Health, U.S. Food and Drug Administration, and the European Medicines Agency. It stands as the first approved gene-editing treatment that addresses the underlying genetic concerns associated with these inherited blood disorders.
Clinical outcomes have showcased remarkable benefits, such as the ability for thalassemia patients to discontinue regular blood transfusions and significant enhancements in life quality for those with sickle cell disease.
Hisham Hagar, Executive Country Manager at Vertex GCC, remarked that the introduction of Casgevy in Qatar signifies a remarkable progression in tackling serious health issues. He praised the collaborative effort with Sidra Medicine and expressed optimism regarding the enduring advantages this therapy can offer eligible patients.
Currently, Sidra Medicine cares for approximately 150 to 200 children diagnosed with thalassemia and sickle cell disease across Qatar.
Dr. Ahmed Al Hammadi, Chair of Pediatric Medicine, emphasized the hospital's commitment to not only provide cutting-edge treatments but also to deliver compassionate, family-focused care. He articulated that Casgevy symbolizes both a scientific advancement and a promise to enhance the lives of young patients.
Chief Research Officer Prof. Khalid Fakhro stated that this accomplishment mirrors Qatar’s dedication to precision health, tailoring treatments to individual genetic characteristics. He reiterated that introducing therapies like Casgevy into the country aligns with Qatar’s ambitions to lead in genomic medicine across the region.
Casgevy has already proven effective for numerous patients worldwide outside of clinical trials, enabling many to achieve independence from blood transfusions and improved quality of life. With this initiative, Sidra Medicine seeks to broaden access to innovative, personalized treatment options, solidifying its role as a leading center for gene and cell therapy in the region.
Canada recorded its first trade surplus in six months as exports rose strongly supported by higher
Canada is considering Swedish and American airborne radar aircraft as part of a multi-billion-dollar
Authorities confirmed that Storage Wars star Darrell Sheets died by suicide at his Arizona home at
Three passengers died and several others fell ill after a suspected hantavirus outbreak aboard a cru
